{
    "id": 26058,
    "cites": 35,
    "cited_by": 0,
    "reference": [
        "Murphy, K.M. and R.H. Topel, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of Health and Longevity.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy, 2006. 114(5): p. 871-904.",
        "Weinstein, M.C. and W.B. Stason, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Foundations of cost-effectiveness analysis for health and medical practices.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d N Engl J Med, 1977. 296(13): p. 716-21.",
        "Lising, A., A. Rosner, J. Gladman, and M. Drummond, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Payers\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Use of ICER Reports in Decision Making,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Association of Managed Care Pharmacy Nexus. 2016, Journal of Managed Care and Specialty Pharmacy: National Harbor, Maryland.",
        "Lakdawalla, D.N., A. Malani, and J. Reif, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The insurance value of medical innovation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics, 2017. 145: p. 94-102.",
        "Lakdawalla, D.N., J.A. Romley, Y. Sanchez, J.R. Maclean, J.R. Penrod, and T. Philipson, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Aff (Millwood), 2012. 31(4): p. 676-82.",
        "Eeckhoudt, L., C. Gollier, and T. Schneider, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Risk-aversion, prudence and temperance: A unified approach.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Economics letters, 1995. 48(3-4): p. 331-336.",
        "Lakdawalla, D.N., J.A. Doshi, L.P. Garrison, Jr., C.E. Phelps, A. Basu, and P.M. Danzon, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Value Health, 2018. 21(2): p. 131-139.",
        "Garber, A.M. and C.E. Phelps, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Economic foundations of cost-effectiveness analysis.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d J Health Econ, 1997. 16(1): p. 1-31.",
        "Markowitz, H., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Portfolio selection.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The journal of finance, 1952. 7(1): p. 77-91.",
        "Pratt, J.W., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Risk Aversion in the Small and in the Large.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, 1964. 32(1): p. 122-36.",
        "Arrow, K.J., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Liquidity preference.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Lecture VI in lecture notes for Economics, 1963. 285: p. 33-53.",
        "Phelps, C.E. and G. Madhavan, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Using multicriteria approaches to assess the value of health care.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Value in Health, 2017. 20(2): p. 251-255.",
        "Alatorre, C., G. Carter, C. Chen, C. Villarivera, V. Zarotsky, R. Cantrell, I. Goetz, R. Paczkowski, and D. Buesching, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International journal of clinical practice, 2011. 65(8): p. 831-847.",
        "Carter, G.C., R.A. Cantrell, V. Zarotsky, V.S. Haynes, G. Phillips, C.I. Alatorre, I. Goetz, R. Paczkowski, and L.B. Marangell, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Comprehensive review of factors implicated in the heterogeneity of response in depression.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Depression and anxiety, 2012. 29(4): p. 340354.",
        "Goetz, I., G.C. Carter, M. Lucero, V. Zarotsky, C.I. Alatorre, R.A. Cantrell, R. Paczkowski, and K.L. Sterling, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Review of treatment response in rheumatoid arthritis: assessment of heterogeneity.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Current medical research and opinion, 2011. 27(4): p. 697-711.",
        "Yu, Y. and J. Cui, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Present and future of cancer immunotherapy: A tumor microenvironmental perspective.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Oncology letters, 2018. 16(4): p. 4105-4113.",
        "Phelps, C., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A New Method to Determine the Optimal Willingness to Pay in CostEffectiveness Analysis.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Value in Health, July, 2019. 22(7):785-791.",
        "Markowitz, H., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Mean\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cvariance approximations to expected utility.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d European Journal of Operational Research, 2014. 234(2): p. 346-355.",
        "Loistl, O., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The erroneous approximation of expected utility by means of a Taylor's series expansion: analytic and computational results.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Economic Review, 1976. 66(5): p. 904-910.",
        "Hlawitschka, W., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The empirical nature of Taylor-series approximations to expected utility.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Economic Review, 1994. 84(3): p. 713-719.",
        "Phelps, C.E., D.N. Lakdawalla, A. Basu, M.F. Drummond, A. Towse, and P.M. Danzon, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Value Health, 2018. 21(2): p. 146-154.",
        "Merton, R.C., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Optimum Consumption and Portfolio Rules in a Continuous-Time Model.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Theory, 1971. 3: p. 373-413.",
        "Kimball, M.S., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Precautionary Motives for Holding Assets,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in The New Palgrave Dictionary of Money and Finance, P. Newman, M. Milgate, and J. Eatwell, Editors. 1992, Macmillan: London.",
        "Shafrin, J., T.T. Schwartz, T. Okoro, and J.A. Romley, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patient Versus Physician Valuation of Durable Survival Gains: Implications for Value Framework Assessments.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Value Health, 2017. 20(2): p. 217-223.",
        "Lakdawalla, D.N., T.J. Philipson, Y. Sanchez, R. Maclean, J.R. Penrod, and J. Romley, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of Hope in Cancer Therapy.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2011, University of Southern California.",
        "Noussair, C.N., S.T. Trautmann, and G. Van de Kuilen, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Higher order risk attitudes, demographics, and financial decisions.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economic Studies, 2013. 81(1): p. 325-355.",
        "Malani, A. and T.J. Philipson, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Can medical progress be sustained? Implications of the link between development and output markets.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2011, Bureau of Economic Research Inc NBER Working Papers: 17011 2011.",
        "Phelps, C.E. and G. Madhavan, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Adverse Events from Medical Treatments (AEMTs) in Healthcare Technology Assessment (HTA).\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2019, University of Rochester.",
        "Yaari, M.E., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Uncertain lifetime, life insurance, and the theory of the consumer.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Review of Economic Studies, 1965. 32(2): p. 137-150.",
        "Bommier, A. and B. Villeneuve, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Risk aversion and the value of risk to life.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Risk and Insurance, 2012. 79(1): p. 77-104.",
        "Bode, B.W., M.A. Testa, M. Magwire, P.M. Hale, M. Hammer, L. Blonde, and A. Garber, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Diabetes, Obesity and Metabolism, 2010. 9999(999A).",
        "Christelis, D., D. Georgarakos, T. Jappelli, and M.v. Rooij, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Consumption Uncertainty and Precautionary Saving.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Review of Economics and Statistics, 2019. Forthcoming: p. 1-45.",
        "Arrow, K.J., Essays in the theory of risk-bearing. Markham Economics Series. 1971, Chicago: Markham Publishing Company.",
        "Romley, J.A., Y. Sanchez, J.R. Penrod, and D.P. Goldman, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs, 2012. 31(4): p. 683-90.",
        "Rothschild, M. and J.E. Stiglitz, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Increasing risk: I. A definition.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic theory, 1970. 2(3): p. 225-243. TABLES AND FIGURES"
    ]
}